Novavax to supply 40M doses of COVID-19 vaccine to South Korea

February 18, 2021

Novavax (NASDAQ:NVAX) and SK Bioscience have expanded their collaboration and license agreement.

In addition to the already existing manufacturing deal, SK Bioscience has obtained a license to manufacture and commercialize NVX-CoV2373, Novavax’s COVID-19 vaccine, for sale to the Korean government.

SK Bioscience has finalized a purchase agreement to supply 40M doses of NVX-CoV2373 to the Republic of Korea beginning in 2021.

Last month, Novavax reported positive interim efficacy results for the vaccine candidate in U.K. NVX-CoV2373 was the first vaccine to demonstrate efficacy against the original strain of COVID-19 and both of the rapidly emerging variants in U.K. and South Africa.

Fundamentals Novavax

For this year the company, located in Gaithersburg revenue will be around 543.9 million USD. This is according to the average of the analysts' estimates. This is quite more than 2019's revenue of 18.66 million USD.

Historical revenues and results Novavax Inc plus estimates 2020

The analysts expect for 2020 a net loss of 304 million USD. According to most of the analysts the company will have a loss per share for this book year of 5.29 USD. So the price/earnings-ratio equals -51.79.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a moderate 0.11 percent.

Novavax Inc 's market capitalization is around 5.27 billion USD. The Novavax Inc stock was the past 12 months quite unstable. Since last February the stock is even 3346 percent higher. This year the stock price moved between 7 and 332 dollar.

Historical stock prices Novavax Inc

Click here for dividend Novavax Inc. At 20.53 the stock trades 2.46 percent lower at 273.98 USD.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.

Sector news

Analysts expect sales decline Biogen

Currently quite high dividend BB Biotech

Analysts: more sales Pharming

Analysts count on revenue increase Pharming

Gilead Sciences in top American dividend stocks

Analysts estimate for 2023 rising sales Sartorius

Currently quite high dividend Abbvie

National news

NXP reaps benefits from FRAMOS collaboration

Tesla net onder de 500.000 cars per year

Analysts expect over 2024 revenue decrease Caterpillar

Analysts expect sales decline Biogen

Analysts anticipate for 2024 on revenue increase Cognizant

Analysts expect over 2024 growing sales Colgate-Palmolive

Analysts expect over 2024 revenue expansion Patterson-UTI Energy, relatively high dividend

Press news

Test News

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Let Poetry Illuminate China's Green City -- The 2nd Nanning International Poetry Week Opens

Light & Wonder, Inc. Announcement: If You Have Suffered Losses in Light & Wonder, Inc. (NASDAQ: LNW), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

BMBL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Bumble Inc. Investors to Secure Counsel Before Important November 25 Deadline in Securities Class Action – BMBL

Unisys Corporation Announcement: If You Have Suffered Losses in Unisys Corporation (NYSE: UIS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Chipotle Mexican Grill, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – CMG

About us	Network	Partners
Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos	Analist.nlLinksISIN Glossary	MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x